🚀 VC round data is live in beta, check it out!
Cassava Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cassava Sciences and similar public comparables like SynAct Pharma, Recce Pharmaceuticals, Cardiol Therapeutics, Darya-Varia Laboratoria and more.
Cassava Sciences Overview
About Cassava Sciences
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Founded
1998
HQ
Employees
30
Website
Sectors
Financials (LTM)
EV
$922K
Cassava Sciences Financials
Cassava Sciences reported last 12-month revenue of —.
In the same LTM period, Cassava Sciences generated had net loss of ($83M).
Revenue (LTM)
Cassava Sciences P&L
In the most recent fiscal year, Cassava Sciences reported revenue of — and net income of —.
Cassava Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Net Profit | ($83M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cassava Sciences Stock Performance
Cassava Sciences has current market cap of $107M, and enterprise value of $922K.
Market Cap Evolution
Cassava Sciences' stock price is $2.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $922K | $107M | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCassava Sciences Valuation Multiples
Cassava Sciences Financial Valuation Multiples
As of March 25, 2026, Cassava Sciences has market cap of $107M and EV of $922K.
Equity research analysts estimate Cassava Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cassava Sciences has a P/E ratio of (1.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV (current) | $922K | XXX | $922K | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | — | XXX | XXX | XXX |
| P/E | (1.3x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cassava Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cassava Sciences Margins & Growth Rates
Cassava Sciences' revenue in the last fiscal year grew by —.
Cassava Sciences' revenue per employee in the last FY averaged $0.0M.
Cassava Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cassava Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SynAct Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Recce Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiol Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Darya-Varia Laboratoria | XXX | XXX | XXX | XXX | XXX | XXX |
| OSE Immunotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cassava Sciences M&A Activity
Cassava Sciences acquired XXX companies to date.
Last acquisition by Cassava Sciences was on XXXXXXXX, XXXXX. Cassava Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cassava Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCassava Sciences Investment Activity
Cassava Sciences invested in XXX companies to date.
Cassava Sciences made its latest investment on XXXXXXXX, XXXXX. Cassava Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cassava Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cassava Sciences
| When was Cassava Sciences founded? | Cassava Sciences was founded in 1998. |
| Where is Cassava Sciences headquartered? | Cassava Sciences is headquartered in United States. |
| How many employees does Cassava Sciences have? | As of today, Cassava Sciences has over 30 employees. |
| Who is the CEO of Cassava Sciences? | Cassava Sciences' CEO is Richard J. Barry. |
| Is Cassava Sciences publicly listed? | Yes, Cassava Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Cassava Sciences? | Cassava Sciences trades under SAVA ticker. |
| When did Cassava Sciences go public? | Cassava Sciences went public in 2000. |
| Who are competitors of Cassava Sciences? | Cassava Sciences main competitors are SynAct Pharma, Recce Pharmaceuticals, Cardiol Therapeutics, Darya-Varia Laboratoria. |
| What is the current market cap of Cassava Sciences? | Cassava Sciences' current market cap is $107M. |
| Is Cassava Sciences profitable? | No, Cassava Sciences is not profitable. |
| What is the current net income of Cassava Sciences? | Cassava Sciences' last 12 months net income is ($83M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.